LYHLT:SW:SW-Multi Units Luxembourg - Amundi STOXX Europe 600 Healthcare UCITS ETF Acc EUR (EUR)

ETF | Others |

Last Closing

USD 153.42

Change

0.00 (0.00)%

Market Cap

USD 0.69B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.02 (+0.14%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.21 (+0.95%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.47 (+1.62%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.07 (-0.24%)

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-11.00 (-0.19%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-9.60 (-0.53%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-6.00 (-0.24%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.75 (+0.93%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.64 (+0.54%)

USD 130,595.12B

ETFs Containing LYHLT:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 6.32% 38% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.32% 36% F 38% F
Trailing 5 Years  
Capital Gain 33.41% 65% D 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.41% 61% D- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 8.99% 71% C- 71% C-
Dividend Return 8.99% 71% C- 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.64% 57% F 62% D
Risk Adjusted Return 117.70% 100% F 99% N/A
Market Capitalization 0.69B 62% D 58% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike